JP2010509342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509342A5 JP2010509342A5 JP2009536338A JP2009536338A JP2010509342A5 JP 2010509342 A5 JP2010509342 A5 JP 2010509342A5 JP 2009536338 A JP2009536338 A JP 2009536338A JP 2009536338 A JP2009536338 A JP 2009536338A JP 2010509342 A5 JP2010509342 A5 JP 2010509342A5
- Authority
- JP
- Japan
- Prior art keywords
- substituent
- methyl
- compound
- pyridin
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 102000004310 Ion Channels Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000005931 immune cell recruitment Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FGGBQDLVIIWCEN-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NC=CS1 FGGBQDLVIIWCEN-UHFFFAOYSA-N 0.000 claims 2
- SLEWYYKLCSEZDR-UHFFFAOYSA-N 2,6-difluoro-n-[5-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]pyrimidin-2-yl]benzamide Chemical compound C1CC(C)=C(C=2C=NC(NC(=O)C=3C(=CC=CC=3F)F)=NC=2)CN1C1=NC=CS1 SLEWYYKLCSEZDR-UHFFFAOYSA-N 0.000 claims 2
- BWGOFNHLWWSJNB-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=NC=CS1 BWGOFNHLWWSJNB-UHFFFAOYSA-N 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- OPXNIJUNTMAHGQ-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-formyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2CN(CCC=2C=O)C=2SC=CN=2)C=C1 OPXNIJUNTMAHGQ-UHFFFAOYSA-N 0.000 claims 1
- WRHLSTUAPDFNPE-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(1,3-oxazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NC=CO1 WRHLSTUAPDFNPE-UHFFFAOYSA-N 0.000 claims 1
- WCEIFOYMXOCFAC-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(1,3-oxazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide;hydrochloride Chemical compound Cl.C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NC=CO1 WCEIFOYMXOCFAC-UHFFFAOYSA-N 0.000 claims 1
- HEFUMIHZJMWLCH-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide;hydrochloride Chemical compound Cl.C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NC=CS1 HEFUMIHZJMWLCH-UHFFFAOYSA-N 0.000 claims 1
- PYJXEYPSJIICDC-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(1-methyltetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NN=NN1C PYJXEYPSJIICDC-UHFFFAOYSA-N 0.000 claims 1
- BCCCDCGGLAACJU-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(2-methyltetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C=1N=NN(C)N=1 BCCCDCGGLAACJU-UHFFFAOYSA-N 0.000 claims 1
- FGQWROFZDNQBQR-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(2h-tetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NN=NN1 FGQWROFZDNQBQR-UHFFFAOYSA-N 0.000 claims 1
- XFZBUOXFDFLOFN-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(4-methyl-1,3-oxazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound CC1=COC(N2CC(=C(C)CC2)C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=N1 XFZBUOXFDFLOFN-UHFFFAOYSA-N 0.000 claims 1
- KYNRZNNDZLLHAS-UHFFFAOYSA-N 2,6-difluoro-n-[5-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]pyridin-2-yl]benzamide;hydrochloride Chemical compound Cl.C1CC(C)=C(C=2C=NC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NC=CS1 KYNRZNNDZLLHAS-UHFFFAOYSA-N 0.000 claims 1
- OWUNKIPWLBWUAI-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(1,3-oxazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=NC=CO1 OWUNKIPWLBWUAI-UHFFFAOYSA-N 0.000 claims 1
- XSOAMLOCFGHNRH-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=NC=CS1 XSOAMLOCFGHNRH-UHFFFAOYSA-N 0.000 claims 1
- LHZRDXHNDGFXRP-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(1-methyltetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=NN=NN1C LHZRDXHNDGFXRP-UHFFFAOYSA-N 0.000 claims 1
- GTCZZGBKBPGJGH-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(2-methyltetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C=1N=NN(C)N=1 GTCZZGBKBPGJGH-UHFFFAOYSA-N 0.000 claims 1
- KKDPVJPVRYNODQ-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(2h-tetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=NN=NN1 KKDPVJPVRYNODQ-UHFFFAOYSA-N 0.000 claims 1
- JQKBHOXSGUGZPJ-UHFFFAOYSA-N 3-methyl-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)CN1C1=NC=CS1 JQKBHOXSGUGZPJ-UHFFFAOYSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- UGWOIYHQWUMROA-UHFFFAOYSA-N 5-methyl-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyrimidine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CN=3)C)=CC=2)CN1C1=NC=CS1 UGWOIYHQWUMROA-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 241000243985 Onchocerca volvulus Species 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 208000024035 chronic otitis media Diseases 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- VXDSWWDKIGLETA-UHFFFAOYSA-N n-[4-[1-(4,5-dimethyl-1,3-oxazol-2-yl)-4-methyl-3,6-dihydro-2h-pyridin-5-yl]phenyl]-2,6-difluorobenzamide Chemical compound O1C(C)=C(C)N=C1N1CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C(C)CC1 VXDSWWDKIGLETA-UHFFFAOYSA-N 0.000 claims 1
- WUEXCPCQSRZDNC-UHFFFAOYSA-N n-[4-[1-(4,5-dimethyl-1,3-oxazol-2-yl)-4-methyl-3,6-dihydro-2h-pyridin-5-yl]phenyl]-5-methylpyrimidine-4-carboxamide Chemical compound O1C(C)=C(C)N=C1N1CC(C=2C=CC(NC(=O)C=3C(=CN=CN=3)C)=CC=2)=C(C)CC1 WUEXCPCQSRZDNC-UHFFFAOYSA-N 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 208000002042 onchocerciasis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000011800 void material Substances 0.000 claims 1
- 0 *[n]1nnnc1N1CC(C(*C(I*)=*)=I)=CCC1 Chemical compound *[n]1nnnc1N1CC(C(*C(I*)=*)=I)=CCC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85861006P | 2006-11-13 | 2006-11-13 | |
| US60/858,610 | 2006-11-13 | ||
| PCT/US2007/023853 WO2008063504A2 (en) | 2006-11-13 | 2007-11-12 | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509342A JP2010509342A (ja) | 2010-03-25 |
| JP2010509342A5 true JP2010509342A5 (enExample) | 2012-01-05 |
| JP5538894B2 JP5538894B2 (ja) | 2014-07-02 |
Family
ID=39430312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536338A Expired - Fee Related JP5538894B2 (ja) | 2006-11-13 | 2007-11-12 | 炎症及び免疫関連使用のためのシクロヘキセニル−アリール化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080207641A1 (enExample) |
| EP (1) | EP2086326B1 (enExample) |
| JP (1) | JP5538894B2 (enExample) |
| AU (1) | AU2007322116B2 (enExample) |
| CA (1) | CA2669695C (enExample) |
| TW (1) | TWI428338B (enExample) |
| WO (1) | WO2008063504A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802721B2 (en) * | 2005-01-25 | 2014-08-12 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
| US8623871B2 (en) * | 2006-01-25 | 2014-01-07 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
| WO2007087441A2 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| US7816535B2 (en) * | 2006-01-25 | 2010-10-19 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| TW200812587A (en) | 2006-03-20 | 2008-03-16 | Synta Pharmaceuticals Corp | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| AR067354A1 (es) | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
| JP2010535218A (ja) * | 2007-08-01 | 2010-11-18 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のためのビニル−アリール誘導体 |
| AU2008299220B2 (en) | 2007-09-10 | 2011-07-21 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8389567B2 (en) | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JPWO2010013849A1 (ja) * | 2008-08-01 | 2012-01-12 | 日本ケミファ株式会社 | Ｇｐｒ１１９作動薬 |
| CA2734500A1 (en) | 2008-08-27 | 2010-03-11 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| WO2010039236A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| EP2477982A4 (en) | 2009-09-16 | 2013-04-03 | Calcimedica Inc | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| JP2013511279A (ja) | 2009-11-20 | 2013-04-04 | アムジエン・インコーポレーテツド | 抗Ｏｒａｉ１抗原結合蛋白及びその使用 |
| EP2532656A1 (en) * | 2010-02-01 | 2012-12-12 | Nippon Chemiphar Co., Ltd. | Gpr119 agonist |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2563759B1 (en) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| HUE029570T2 (en) | 2010-04-27 | 2017-03-28 | Calcimedica Inc | Intracellular calcium modifying compounds |
| US9079891B2 (en) | 2010-08-27 | 2015-07-14 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2638032A1 (en) * | 2010-11-09 | 2013-09-18 | Synta Pharmaceuticals Corp. | Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9856240B2 (en) | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2016224993B2 (en) | 2015-02-27 | 2019-11-21 | Calcimedica, Inc. | Pancreatitis treatment |
| DK3331525T3 (da) | 2015-08-07 | 2020-12-14 | Calcimedica Inc | Anvendelse af CRAC-kanal-inhibitorer til behandling af slagtilfælde og traumatisk hjerneskade |
| KR101798840B1 (ko) * | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
| US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
| BR112021004893A2 (pt) | 2018-09-14 | 2021-06-01 | Rhizen Pharmaceuticals A G | composições compreendendo um inibidor de crac e um corticosteroide e métodos de uso dos mesmos |
| IL294504A (en) | 2020-01-13 | 2022-09-01 | Verge Analytics Inc | Converted pyrazolo-pyrimidines and their uses |
| US12522589B2 (en) | 2020-11-13 | 2026-01-13 | Calcimedica, Inc. | Synthesis of CRAC channel inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| JP2000256358A (ja) * | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
| US6720317B1 (en) * | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP4744050B2 (ja) * | 1999-09-17 | 2011-08-10 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ベンズアミドおよび関連するＸａ因子阻害剤 |
| BRPI0414313A (pt) * | 2003-09-11 | 2006-11-07 | Kemia Inc | inibidores de citocinas |
| US7531560B2 (en) * | 2004-11-10 | 2009-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
| KR20140018997A (ko) * | 2005-01-07 | 2014-02-13 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| ZA200707125B (en) * | 2005-01-25 | 2008-11-26 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
| US7816535B2 (en) * | 2006-01-25 | 2010-10-19 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
-
2007
- 2007-11-12 JP JP2009536338A patent/JP5538894B2/ja not_active Expired - Fee Related
- 2007-11-12 AU AU2007322116A patent/AU2007322116B2/en not_active Ceased
- 2007-11-12 EP EP07853118.3A patent/EP2086326B1/en not_active Not-in-force
- 2007-11-12 US US11/938,779 patent/US20080207641A1/en not_active Abandoned
- 2007-11-12 CA CA2669695A patent/CA2669695C/en not_active Expired - Fee Related
- 2007-11-12 WO PCT/US2007/023853 patent/WO2008063504A2/en not_active Ceased
- 2007-11-13 TW TW096142793A patent/TWI428338B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509342A5 (enExample) | ||
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2010535218A5 (enExample) | ||
| JP2012504605A5 (enExample) | ||
| JP2010535214A5 (enExample) | ||
| JP2010519206A5 (enExample) | ||
| JP2010535215A5 (enExample) | ||
| ES2280768T3 (es) | Inhibidores de histona desacetilasa. | |
| JP2019163290A5 (enExample) | ||
| JP2020537657A5 (enExample) | ||
| JP2012504604A5 (enExample) | ||
| AU2006307314B2 (en) | Aminodihydrothiazine derivative | |
| JP2006528980A5 (enExample) | ||
| CA2475712A1 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
| JP4669836B2 (ja) | ピペリジニル−およびピペラジニル−アルキルカルバメート誘導体、その製造法および治療用途 | |
| ES2405054T3 (es) | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato | |
| JP2008513508A5 (enExample) | ||
| RU2018137194A (ru) | Ингибиторы бромдомена | |
| JP2007515432A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2017505808A5 (enExample) | ||
| CA2477774A1 (en) | Indolylmaleimide derivatives | |
| JP2010540593A5 (enExample) | ||
| JP2018525379A5 (enExample) | ||
| JP2009532366A5 (enExample) |